Tonix Pharmaceuticals Holding (TNXP) Depreciation & Amortization (CF) (2011 - 2026)

Tonix Pharmaceuticals Holding's Depreciation & Amortization (CF) history runs 16 years deep, the most recent figure standing at $555000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 12.58% year-over-year to $555000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 26.52% decrease from a year earlier, with the FY2025 full-year figure at $1.9 million, down 43.73% from the prior year.
• Depreciation & Amortization (CF) rose to $555000.0 in Q1 2026 per TNXP's latest filing, from $488000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.3 million in Q4 2023 and bottomed at $63000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $510000.0 (2024), against an average of $672000.0.
• Across the five-year window, Depreciation & Amortization (CF) surged 2996.3% in 2022 and tumbled 60.67% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $836000.0 in 2022, then soared by 50.84% to $1.3 million in 2023, then slumped by 60.67% to $496000.0 in 2024, then dropped by 1.61% to $488000.0 in 2025, then increased by 13.73% to $555000.0 in 2026.
• Per Business Quant, the three latest TNXP Depreciation & Amortization (CF) figures stand at $555000.0 (Q1 2026), $488000.0 (Q4 2025), and $461000.0 (Q3 2025).